Wall Street Zen Upgrades Lipocine (NASDAQ:LPCN) to “Hold”

Lipocine (NASDAQ:LPCN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

Other equities analysts have also issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $15.00 price objective (up from $7.00) on shares of Lipocine in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Lipocine Trading Up 2.2%

Shares of Lipocine stock opened at $7.31 on Friday. The company has a market cap of $53.36 million, a PE ratio of -4.34 and a beta of 0.98. The company has a 50 day moving average of $9.03 and a 200-day moving average of $5.56. Lipocine has a 1-year low of $2.52 and a 1-year high of $12.37.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Monday, March 9th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%. The business had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $0.12 million.

Institutional Trading of Lipocine

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its stake in shares of Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after buying an additional 1,300 shares during the last quarter. Diadema Partners LP bought a new position in shares of Lipocine in the 4th quarter valued at $2,095,000. Squadron Capital Management LLC acquired a new stake in shares of Lipocine during the 4th quarter valued at $4,256,000. Ikarian Capital LLC acquired a new stake in shares of Lipocine during the 4th quarter valued at $1,602,000. Finally, Geode Capital Management LLC grew its position in Lipocine by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after acquiring an additional 1,374 shares during the last quarter. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.